143 related articles for article (PubMed ID: 38597264)
1. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract][Full Text] [Related]
2. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
[TBL] [Abstract][Full Text] [Related]
3. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
[TBL] [Abstract][Full Text] [Related]
4. MCL-1 inhibitors - where are we now (2019)?
Fletcher S
Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
[No Abstract] [Full Text] [Related]
5. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
[TBL] [Abstract][Full Text] [Related]
6. Development of Mcl-1 inhibitors for cancer therapy.
Negi A; Murphy PV
Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
[TBL] [Abstract][Full Text] [Related]
7. Targeting MCL-1 in cancer: current status and perspectives.
Wang H; Guo M; Wei H; Chen Y
J Hematol Oncol; 2021 Apr; 14(1):67. PubMed ID: 33883020
[TBL] [Abstract][Full Text] [Related]
8. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
Zhu PJ; Yu ZZ; You QD; Jiang ZY
Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of Mcl-1 inhibitors for cancer therapy.
Hird AW; Tron AE
Pharmacol Ther; 2019 Jun; 198():59-67. PubMed ID: 30790641
[TBL] [Abstract][Full Text] [Related]
11. Small molecule Mcl-1 inhibitors for the treatment of cancer.
Belmar J; Fesik SW
Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548
[TBL] [Abstract][Full Text] [Related]
12. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.
Yamaguchi R; Lartigue L; Perkins G
Pharmacol Ther; 2019 Mar; 195():13-20. PubMed ID: 30347215
[TBL] [Abstract][Full Text] [Related]
13. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
[TBL] [Abstract][Full Text] [Related]
15. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
[TBL] [Abstract][Full Text] [Related]
16. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
[TBL] [Abstract][Full Text] [Related]
17. Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.
Senichkin VV; Streletskaia AY; Zhivotovsky B; Kopeina GS
Trends Cell Biol; 2019 Jul; 29(7):549-562. PubMed ID: 31030977
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
19. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
20. Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.
Romanov-Michailidis F; Hsiao CC; Urner LM; Jerhaoui S; Surkyn M; Miller B; Vos A; Dominguez Blanco M; Bueters R; Vinken P; Bekkers M; Walker D; Pietrak B; Eyckmans W; Dores-Sousa JL; Joo Koo S; Lento W; Bauser M; Philippar U; Rombouts FJR
J Med Chem; 2023 May; 66(9):6122-6148. PubMed ID: 37114951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]